We have located links that may give you full text access.
JOURNAL ARTICLE
META-ANALYSIS
RESEARCH SUPPORT, NON-U.S. GOV'T
REVIEW
Incidence and risk factors for heterotopic ossification after total hip arthroplasty: a meta-analysis.
Archives of Orthopaedic and Trauma Surgery 2015 September
BACKGROUND: This study aims to quantitatively summarize risk factors associated with heterotopic ossification after total hip arthroplasty.
METHODS: The computerized and additional manual searches were performed in Medline, Embase, CNKI, and Cochrane central database (all through March 2014) for potential studies. Studies eligible had to meet the quality assessment criteria by Newcastle-Ottawa Scale and to evaluate the risk factors for heterotopic ossification after total hip arthroplasty. Two reviewers independently extracted the relevant data and any disagreement was solved by consensus. Stata11.0 was used to perform all the statistical analyses.
RESULTS: Fourteen studies involving 6468 cases with total hip arthroplasty and 1939 heterotopic ossification (HOs) (30.0 %) were eligible and included in this meta-analysis. Our meta-analysis identified the significant increased risk factors for HO were male gender [odds ratio (OR) 2.11; 95 % confidence interval (CI) 1.80-2.48)], cemented implant (OR 1.48; 95 % CI 1.00-2.17), bilateral operations (OR 1.74; 95 % CI 1.24-2.45), ankylosing spondylitis (OR 1.90; 95 % CI 1.07-3.37) and ankylosed hip (OR 9.85; 95 % CI 2.61-37.24). Rheumatoid arthritis was protective for the development of HO (OR 0.51; 95 % CI 0.33-0.80). The other variables including age, use of NSAIDs, femoral neck fracture, previous hip fracture, hypertrophic osteoarthritis and osteophytes were identified not as the risk factors for development of HO (P > 0.05).
CONCLUSION: Patients involved with the above-mentioned medical conditions should be carefully paid close attention by surgeons to reduce HO after total hip arthroplasty.
LEVEL OF EVIDENCE: Level II, meta-analysis.
METHODS: The computerized and additional manual searches were performed in Medline, Embase, CNKI, and Cochrane central database (all through March 2014) for potential studies. Studies eligible had to meet the quality assessment criteria by Newcastle-Ottawa Scale and to evaluate the risk factors for heterotopic ossification after total hip arthroplasty. Two reviewers independently extracted the relevant data and any disagreement was solved by consensus. Stata11.0 was used to perform all the statistical analyses.
RESULTS: Fourteen studies involving 6468 cases with total hip arthroplasty and 1939 heterotopic ossification (HOs) (30.0 %) were eligible and included in this meta-analysis. Our meta-analysis identified the significant increased risk factors for HO were male gender [odds ratio (OR) 2.11; 95 % confidence interval (CI) 1.80-2.48)], cemented implant (OR 1.48; 95 % CI 1.00-2.17), bilateral operations (OR 1.74; 95 % CI 1.24-2.45), ankylosing spondylitis (OR 1.90; 95 % CI 1.07-3.37) and ankylosed hip (OR 9.85; 95 % CI 2.61-37.24). Rheumatoid arthritis was protective for the development of HO (OR 0.51; 95 % CI 0.33-0.80). The other variables including age, use of NSAIDs, femoral neck fracture, previous hip fracture, hypertrophic osteoarthritis and osteophytes were identified not as the risk factors for development of HO (P > 0.05).
CONCLUSION: Patients involved with the above-mentioned medical conditions should be carefully paid close attention by surgeons to reduce HO after total hip arthroplasty.
LEVEL OF EVIDENCE: Level II, meta-analysis.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app